The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer

Authors :: Michael Friedlander
Sonia Yip
Michael A. Quinn
Magdalena Plebanski
Kerri Carlton
Jeffrey C. Goh
David D.L. Bowtell
Kim Gillies
Catherine Shannon
Julie Martyn
Katrin Marie Sjoquist
Linda Mileshkin
Val Gebski
Source :: Journal of Clinical Oncology. 32:TPS5627-TPS5627
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: TPS5627 Background: We hypothesise that intraperitoneal (IP) administration of bevacizumab will reduce formation, and delay time to re-accumulation, of ascites in patients with malignant ascites an...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
medicine.disease
Internal medicine
Ascites
medicine
Chemotherapy resistant
In patient
medicine.symptom
Ovarian cancer
business
medicine.drug
Delay time

Full Text Access

Tools